Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

British Journal of Cancer

Volumn 115, Issue 10, 2016, Pages 1215-1222

  Karthaus, Meinolf ^a   Hofheinz, Ralf Dieter ^b   Mineur, Laurent ^c   Letocha, Henry ^d   Greil, Richard ^e   Thaler, Josef ^f   Fernebro, Eva ^g   Oliner, Kelly S ^h   Boedigheimer, Michael ^h   Twomey, Brian ^h   Zhang, Ying ^h   Demonty, Gaston ^h   Köhne, Claus Henning ⁱ  

^a 1Klinikum Neuperlach Klinikum Harlaching   (Germany)

^b Universita Tsmedizin Mannheim   (Germany)

^c INSTITUT SAINTE CATHERINE   (France)

^d Section of Vascular Surgery   (Sweden)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f Klinikum Wels Grieskirchen GmbH   (Austria)

^g CENTRAL HOSPITAL   (Sweden)

^h AMGEN INC   (United States)

ⁱ KLINIKUM OLDENBURG   (Germany)

Author keywords

amphiregulin; BRAF; KRAS; metastatic colorectal cancer; NRAS; Panitumumab; RAS; response

Indexed keywords

AMPHIREGULIN; B RAF KINASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; MONOCLONAL ANTIBODY; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; EXON; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE N RAS; ONCOGENE RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SKIN TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC); PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

AMPHIREGULIN; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; IFL PROTOCOL; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; PANITUMUMAB; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES;

EID: 84992026538     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.343     Document Type: Article

References (37)

1. Abad A, Massuti B, Gravalos C, Escudero P, Guillen C, Manzano JL, Gomez MA, Safont MJ, Plazas JG, Sastre J, Pericay C, Duenãs R, Loez-Loez C, Losa F, Ayerbes MV, Gonzaez E, Yuste A, Carrato A, Aranda E (2014) Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: the PLANET study. J Clin Oncol 32(5 Suppl): Abstract 3560.
2. Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, Rowinsky EK, Xu LA, Harbison CT, Clark EA, Mauro DJ, Khambata-Ford S (2011) Tumour gene expression predicts response to cetuximab in patients with KRAS wildtype metastatic colorectal cancer. Br J Cancer 104: 488-495.
3. Bennett L, Zhao Z, Barber B, Zhou X, Peeters M, Zhang J, Xu F, Wiezorek J, Douillard JY (2011) Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first-or secondline treatment. Br J Cancer 105: 1495-1502.
4. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546.
5. Bokemeyer C, Kone CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51: 1243-1252.
6. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with antiepidermal growth factor receptor therapy: survey results. Oncology 72: 152-159.
7. Ciardiello F, Lenz H-J, Kohne CH, Heinemann V, Tejpar S, Esser R, Beier F, Stroh C, Duecker K, Van Cutsem E (2014) Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): new results from the CRYSTAL trial. J Clin Oncol 32(Suppl 3): Abstract #LBA443.
8. Cohn AL, Shumaker GC, Khandelwal P, Smith DA, Neubauer MA, Mehta N, Richards D, Watkins DL, Zhang K, Yassine MR (2011) An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 10: 171-177.
9. Douillard JY, Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocaova I, Ruff P, B"asinka-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034.
10. Douillard JY, Siena S, Peeters M, Koukakis R, Terwey JH, Tabernero J (2015) Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 51: 1231-1242.
11. Heinemann, V, Modest D, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Lerchenmuler C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen C, Moler M, Jagenburg A, Stintzing S (2014a) Independent radiological evaluation of objective response by early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306). Ann Oncol 25(Suppl 2): ii117 Abstract O-0030.
12. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuler C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Muler S, Link H, Niederle N, Rost A, Hofkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S (2014b) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, openlabel, phase 3 trial. Lancet Oncol 15: 1065-1075.
13. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Peault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27: 5068-5074.
14. Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13: 265-274.
15. Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RP, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S (2014) Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 110: 648-655.
16. Kone CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M (2012) First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138: 65-72.
17. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28: 1351-1357.
18. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, Faviana P, Sensi E, Lupi C, Fontanini G, Basolo F, Di Paolo A, Danesi R, Falcone A, Bocci G (2014) EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol 9: 205-214.
19. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M (2009) Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16: 16-26.
20. Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV, Xu F, Yassine M (2011) The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer 10: 333-339.
21. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S (2014) Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13: 164-171.
22. National Comprehensive Cancer Network (2015) NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. V2. 2015. Jamestown, PA: National Comprehensive Cancer Network.
23. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, AndreT, Wiezorek J, Reese D, Patterson SD (2013) Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19: 1902-1912.
24. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJA, Strickland A, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Yu H, Jung AS, Sidhu R, Patterson SD (2014a) Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 32(Suppl 5): Abstract #3568.
25. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJA, Strickland A, Wilson G, Ciuleanu T-E, Roman L, Van Cutsem E, Tian Y, Jung AS, Sidhu R, Patterson SD (2014c) Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 32(Suppl 3): Abstract #LBA387.
26. Peeters M, Price TJ, Cervantes A, Sobrero A, Ducreux MP, AndreT, Lordick F, Punt CJA, Koukakis R, Terwey J, van Custem E (2014b) Tumour shrinkage and response outcomes during second-line panitumumab (pmab)\+FOLFIRI vs FOLFIRI treatment. Ann Oncol 25(Suppl 4): Abstract #7739 (546P).
27. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G (2013) Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13: 49.
28. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, Baron JA, Ahnen DJ, Win AK, Potter JD, Newcomb PA (2012) BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 21: 1792-1798.
29. Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, Antoniotti C, de Braud F, Falcone A, Iacovelli R (2015) First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 96: 156-166.
30. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer (2015) Br J Cancer 112: 1888-1894.
31. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32: 2240-2247.
32. Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Held S, von Einem JC, Holch J, Neumann J, Kirchner T, Jung A, Modest DP (2016) Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). Int J Cancer 138: 739-746.
33. Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Banõs A, Kone CH (2012) Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 12: 438.
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
35. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33: 692-700.
36. Vanhatalo J, Riihimai J, Hartikainen J, Jylaki P, Tolvanen V, Vehtari A (2013) GPstuff: Bayesian modeling with Gaussian processes. J Mach Learn Res 14: 1179.
37. Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. Cancer and Leukemia Group B (Alliance), SWOG, and ECOG (2014) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32(5 Suppl): Abstract LBA3.